CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 237 enrolled
Drug / intervention
XR-NTX (Extended-Release Naltrexone) +1 moredrug
Likely dose
XR-NTX (Extended-Release Naltrexone) 380mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01893827
NCT01893827Phase 4Completed

Randomized, Open-label Clinical Trial of Extended-Release vs. Oral Naltrexone for Alcohol Treatment in Primary Care.

NYU Langone Health·interventional·Posted Jul 9, 2013·Updated Jun 16, 2020

In Brief

A Phase 4 clinical trial evaluating XR-NTX (Extended-Release Naltrexone) and Oral Naltrexone (O-NTX) for Alcohol Dependence. Completed, enrolled 237 participants across 1 site.

Detailed Summary

The proposed study is a pragmatic, randomized, open-label clinical trial of 24 weeks of XR-NTX vs. O-NTX using a COMBINE-adapted Medical Management primary care treatment model. 237 adults \>18yo with alcohol dependence will be recruited from the community into treatment in public sector primary care settings. The primary outcome which powers this study is a dichotomous good clinical outcome defined by abstinence or moderate drinking, and as measured by the Timeline Follow-back and analyzed using an intention-to-treat approach among all randomized participants. Secondary outcomes include the incremental cost effectiveness of the two arms, differences between arms by continuous measures of alcohol intake (drinks/day, % days abstinent, time to first heavy drinking day, bio-markers), and the exploratory analysis of factors possibly associated with effectiveness, including gender, prior treatment abstinence, and mu opioid receptor (OPRM1) genotypes. Specific Aim 1: Treatment Effectiveness. To evaluate the effectiveness of extended-release naltrexone (XR-NTX) vs. oral naltrexone (O-NTX) in producing a primary good clinical outcome, defined as abstinence or moderate drinking (≤2 drinks/day, men; ≤1 drink/day,women; and ≤2 heavy drinking occasions/month), during the final 20 of 24 weeks of primary care-based Medical Management for alcohol dependence. Hypothesis: The rate of this good clinical outcome will be approximately twice as great among participants receiving XR-NTX compared with those receiving O-NTX. Specific Aim 2: Cost Effectiveness. To estimate the incremental cost effectiveness of XR-NTX vs. O-NTX,both in conjunction with primary care-based Medical Management. Hypothesis: XR-NTX treatment will be more cost effective than O-NTX. Specific Aim 3: Patient-Level Predictors of Effectiveness. To identify patient-level characteristics associated with effectiveness in both arms.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

Phase 4CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedJul 9, 2013
Enrollment StartJun 1, 2014
Primary CompletionOct 3, 2018
TodayJul 2, 2026
Enrollment to primary: 4.3 yearsPosted 13.0 years ago

Interventions

XR-NTX (Extended-Release Naltrexone)drug

380mg (4cc) XR-NTX administered by IM injection 1x/month for 6 months.

Oral Naltrexone (O-NTX)drug

50mg pill form of naltrexone taken 1x/day for 6 months.